Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Epratuzumab

Criteria

Inclusion Criteria:

• +ANA at screening

• BILAG Index B Level Activity in at least 2 body systems/organs

• Has SLE by ACR revised criteria (meets,<4 criteria)

Exclusion Criteria:

• Active Severe Lupus as defined by BILAG Index Level A in any body system or organ.

• Allergy to human antibodies or Murine.